An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?
Open Access
- 24 November 2011
- journal article
- research article
- Published by Springer Nature in BMC Public Health
- Vol. 11 (1) , 892
Abstract
When a medicine such as rofecoxib (Vioxx) is withdrawn, or a whole class of medicines discredited such as the selective COX-2 inhibitors (COX-2s), follow-up of impacts at consumer level can be difficult and costly. The Australian Longitudinal Study on Women's Health provides a rare opportunity to examine individual consumer medicine use following a major discrediting event, the withdrawal of rofecoxib and issuing of safety warnings on the COX-2 class of medicines. The overall objective of this paper was to examine the impact of this discrediting event on dispensing of the COX-2 class of medicines, by describing medicine switching behaviours of older Australian women using rofecoxib in September 2004; the uptake of other COX-2s; and the characteristics of women who continued using a COX-2.Keywords
This publication has 38 references indexed in Scilit:
- How Do Different Age Groups Use Benzodiazepines and Antidepressants?Drugs & Aging, 2009
- Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxibArthritis Care & Research, 2008
- Accuracy of Telephone Self-Report of Drug Use in Older People and Agreement with Pharmaceutical Claims DataDrugs & Aging, 2008
- What happened to the prescribing of other COX‐2 inhibitors, paracetamol and non‐steroidal anti‐inflammatory drugs when rofecoxib was withdrawn in Australia?Pharmacoepidemiology and Drug Safety, 2007
- What therapies have replaced rofecoxib in Ireland?British Journal of Clinical Pharmacology, 2007
- Characterizing new users of NSAIDs before and after rofecoxib withdrawalBritish Journal of Clinical Pharmacology, 2007
- The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in ScotlandBritish Journal of Clinical Pharmacology, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Health services research using linked records: who consents and what is the gain?Australian and New Zealand Journal of Public Health, 2001